FDA Approves SynGenX-1000 Cord Blood Processing Platform

by Savitha C Muppala on  July 20, 2013 at 12:23 PM Medical Gadgets
RSS Email Print This Page Comment
Font : A-A+

A company that makes products for extracting stem cells from a variety of sources, SynGen Inc., of Sacramento, CA, has received the FDA nod for its SynGenX-1000 platform.

The SynGenX-1000 platform is capable of harvesting stem cells from umbilical cord blood.
 FDA Approves SynGenX-1000 Cord Blood Processing Platform
FDA Approves SynGenX-1000 Cord Blood Processing Platform

Philip Coelho, CEO of SynGen, said "This 'next generation' SynGenX™-1000 System improves the recovery of stem and progenitor cells from cord blood units, which should increase the number of clinical grade units available for transplantation. The CryoPRO-2™ simplifies the cryopreservation workflow for cord blood bank personnel and provides a medical record of the process. The SynGen™ DataTrak software captures the data associated with processing each cord blood unit for the blood bank's records."



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Stem Cells - Cord Blood Thalassemia Stem Cells - Fundamentals Tissue Engineering and Regenerative Medicine Stem Cells Blood in Stools - Symptom Evaluation Bombay Blood Group 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive